第 一 财 经 持 续 追 踪 财 经 热 点 。 若 您 掌 握 公 司 动 态 、 行 业 趋 势 、 金 融 事 件 等 有 价 值 的 线 索 ， 欢 迎 提 供 。 专 用 邮 箱 ： bianjibu@yicai.com （注：我们会对线索进行核实。您的隐私将严格保密。） 推荐阅读 多个"新大学"首年招生分数线直超985高校，原因何在 2025.07. 26 本文字数：432，阅读时长大约1分钟 7月26日，华熙生物官方微博发布《关于网络不实信息的严正声明》 称，昨日晚间发现部分网络平台 用户发布关于公司的严重不实信息。经核实，信息发布于境外网站，内容纯属捏造，恶意歪曲事实， 其中部分内容涉及政治谣言，性质极其恶劣。经查，该信息发布者李某曾任华熙昕宇投资有限公司市 场部总监，事发前曾在华熙工作18个月。2018年，李某通过个人注册第三方公司的方式骗取本应支 付给券商的900万元，此后券商在查看华熙昕宇年报时发现该笔款项，李某职务侵占的事情真相遂败 露。基于上述情况，公司在此严正声明，相关信息是毫无道德底线的编造，涉嫌诽谤犯罪，公司已向 公安机关报案，并已向有关部门举报，依法追究造谣者及恶意传播者的 ...

Core Viewpoint - The "2025 China Sci-Tech Leaders Conference and the 6th Anniversary of the Sci-Tech Innovation Board" highlighted the integration of technology innovation and capital markets, emphasizing the role of the Sci-Tech Innovation Board in supporting China's technological advancements and industrial upgrades [2][5][22]. Group 1: Conference Overview - The conference featured 9 keynote speeches, 2 roundtable discussions, and various forums, attracting over 80 leaders from listed companies and nearly 1,000 attendees [2]. - Keynote speeches addressed topics such as semiconductor technology, AI, and innovative pharmaceuticals, showcasing the diverse fields of innovation [7][9][10]. Group 2: Government and Institutional Support - The Shanghai Municipal Government emphasized the importance of the Songjiang District in advancing manufacturing and technology innovation, focusing on high-end equipment and new-generation information technology [4]. - The Shanghai Stock Exchange reiterated its commitment to supporting "hard technology" and enhancing the "technology-industry-capital" cycle to align with national strategic needs [5]. Group 3: Industry Insights - Industry leaders discussed the challenges and opportunities in the semiconductor sector, highlighting the need for internationalization and innovation in the face of global competition [9]. - The conference revealed structural issues within the Sci-Tech Innovation Board, such as market capitalization dispersion and low delisting rates, which need to be addressed for better resource allocation [7]. Group 4: Mergers and Acquisitions - A roundtable discussion on mergers and acquisitions highlighted the evolving landscape, with a focus on strategic growth and industry chain restructuring rather than merely increasing market capitalization [13][15]. - The current M&A environment is characterized by a buyer's market for listed companies, emphasizing the importance of synergies and realistic valuations [15]. Group 5: International Expansion - Discussions on international expansion revealed a shift from cost advantages to technological advantages, with companies focusing on ecosystem outputs and proactive participation in standard-setting [17]. - The need for data security and software safety in overseas markets was underscored, as companies adapt to geopolitical challenges [17]. Group 6: Industry Collaboration - The conference facilitated connections between technology and capital demands, with a focus on high-barrier technology fields such as semiconductors and medical devices [21]. - The establishment of the "Best ESG Sci-Tech Innovation Board Listed Company" award aims to provide a reference for evaluating ESG performance in the industry [21]. Group 7: Future Outlook - The Sci-Tech Innovation Board has seen significant growth, with 589 listed companies and a total market capitalization exceeding 7.5 trillion yuan, positioning it as a key player in China's technological innovation landscape [22].

Group 1 - The core idea of the news is that Meituan's "Safe Beauty" initiative is significantly enhancing consumer trust in the medical beauty industry through AIoT smart verification hardware and services, leading to increased user satisfaction and repeat purchase intentions [1][2] - By June 2025, Meituan's "Safe Beauty" has provided over 7 million verification services and installed more than 4,000 self-developed AIoT smart verification devices for over 2,000 medical beauty institutions [1] - Over 88.6% of users who experienced the "Safe Beauty" verification process expressed a desire to continue choosing institutions with similar verification services on the platform [1] Group 2 - In the first half of 2025, more than 15 upstream brands joined the "Safe Beauty 100,000 Verification Club," with a total of over 100,000 verifications conducted [2] - The overall brand scale using "Safe Beauty" smart verification devices increased by 13.1% compared to 2024 [2] - There is a notable increase in user attention towards the qualifications and professional backgrounds of medical staff [2]

北京商报讯（记者 丁宁）7月26日，华熙生物在微博发布"关于网络不实信息的严正声明"。声明指出， 公司于昨日晚间发现部分网络平台用户发布关于华熙生物的严重不实信息。经核实，该信息发布于境外 网站，内容纯属捏造，歪曲事实，严重损害公司声誉。 基于上述情况，华熙生物表示，相关信息是毫无道德底线的编造，涉嫌诽谤犯罪，我司已向公安机关报 案，并已向有关部门举报，依法追究造谣者及恶意传播者的法律责任。 华熙生物于2019年登陆科创板，素有"玻尿酸第一股"之称。公司最新收盘价为53.83元/股，总市值为 259.3亿元。 今年一季度，公司实现营业收入10.78亿元，同比下降20.77%；对应实现的归属净利润1.02亿元，同比 下降58.13%。 华熙生物表示，经查，该信息发布者李某曾任华熙昕宇投资有限公司（以下简称"华熙昕宇"）市场部总 监，事发前在华熙工作18个月。2018年，李某通过个人注册第三方公司的方式骗取本应支付给券商的 900万元，此后券商在查看华熙昕宇年报时发现该笔款项，李某职务侵占的事情真相遂败露。 事发后，华熙昕宇立即向公安机关报案。公安机关经立案侦查，依据《中华人民共和国刑法》第二百七 十一条规定的职 ...

Core Viewpoint - The company has issued a stern statement regarding the dissemination of false information that severely damages its reputation, asserting that it will pursue legal action against the perpetrators [1][3]. Group 1: Incident Overview - On July 26, the company announced that it discovered serious false information about itself being circulated on foreign websites, which it claims is fabricated and maliciously distorts facts [1]. - The individual responsible for the false information, identified as Li, previously served as the marketing director at Huaxi Xinyu Investment Co., Ltd. for 18 months [1]. - In 2018, Li fraudulently obtained 9 million yuan (approximately 1.3 million USD) that was supposed to be paid to a brokerage, leading to his exposure and subsequent legal action [1]. Group 2: Legal Actions - The company has reported the matter to law enforcement and is pursuing legal accountability for defamation against those spreading the false information [1][3]. - The police have initiated an investigation into Li's actions, which fall under the crime of embezzlement as per Article 271 of the Criminal Law of the People's Republic of China [1]. Group 3: Apology and Compensation - Li issued a letter of apology to the company, acknowledging his wrongdoing and expressing regret for the negative impact on the company's reputation [9]. - In his apology, Li promised to return the embezzled 9 million yuan and offered an additional 1.5 million yuan (approximately 220,000 USD) as compensation for his actions [9].

Core Viewpoint - A former employee of Huaxi Biological, claiming to be "David," has made serious allegations of financial misconduct against the company, which Huaxi Biological has strongly denied, stating that the claims are false and defamatory [2][4][9]. Group 1: Allegations and Responses - "David" claims to have been a senior assistant to the CEO and has written extensively about the company, although only a table of contents and summaries have been published [2]. - Huaxi Biological responded via its official Weibo, asserting that the allegations are fabricated and have been reported to the authorities [4][9]. - The individual behind the allegations, identified as Li, previously worked at Huaxi and was involved in a financial misconduct case where he embezzled 9 million yuan (approximately 1.3 million USD) [5]. Group 2: Legal Actions and Company Stance - Huaxi Biological has stated that it will pursue legal action against the individual for defamation and has already reported the matter to law enforcement [9]. - The company provided evidence of Li's previous misconduct, including a letter of apology where he admitted to serious violations during a bond issuance process [7][5]. - Huaxi Biological emphasized that the allegations are morally baseless and have severely damaged its reputation [4][9].

针对部分网络平台用户发布的相关信息，医美巨头华熙生物官方微博7月26日发布声明称，内容纯属捏造，恶 意歪曲事实，涉嫌诽谤犯罪，公司已向公安机关报案，并向有关部门举报，依法追究造谣者及恶意传播者的法 律责任。 华熙生物官方微博称，"昨日晚间，我司发现部分网络平台用户发布关于我司的严重不实信息。经核实，该信 息发布于境外网站，内容纯属捏造，恶意歪曲事实，严重损害我司声誉，其中部分内容涉及政治谣言，性质极 其恶劣。" 据华熙生物介绍，该信息发布者李某曾任华熙昕宇投资有限公司市场部总监，事发前在华熙工作18个月。 2018年，李某通过个人注册第三方公司的方式骗取本应支付给券商的900万元，此后券商在查看华熙昕宇年 报时发现该笔款项，李某职务侵占的事情真相遂败露。 事发后，华熙昕宇立即向公安机关报案。公安机关经立案侦查（立案回执见附件），依据《中华人民共和国刑 法》第二百七十一条规定的职务侵占罪移送司法机关提起公诉。公安机关侦查期间，为减轻罪责，李某向公司 写下了道歉信（原文见附件），公司坚持依法办事，对其提出的除退还900万元侵占款外额外给予赔偿的要求 不予置理。 来 源：华 熙 生 物 微 博 责 编：刘 珺 宇 ...

Core Viewpoint - Huaxi Bio has officially responded to false information circulating on social media, claiming it is fabricated and maliciously distorts facts, and has reported the matter to law enforcement [2][3]. Group 1: Company Response - The company stated that the false information was posted by users on foreign websites and severely damages its reputation, with some content involving political rumors [3]. - Huaxi Bio has filed a police report and is pursuing legal action against the individuals responsible for spreading the false information [2][4]. Group 2: Background Information - The individual responsible for the false information, identified as Li, previously served as the marketing director at Huaxi Xinyu Investment Co., Ltd. for 18 months [4]. - Li was involved in a case of embezzlement, having fraudulently obtained 9 million yuan that was supposed to be paid to a brokerage, which was discovered during an annual report review [4]. - Following the incident, Huaxi Xinyu reported the case to law enforcement, leading to Li being prosecuted for embezzlement under Chinese law [4]. Group 3: Financial Impact - On July 25, Huaxi Bio's stock closed at 53.83 yuan per share, with a market capitalization of 25.9 billion yuan [4].

Core Viewpoint - Huaxi Biological has officially responded to false information circulating on online platforms, claiming that the content is fabricated and maliciously distorts facts, which has severely damaged the company's reputation. The company has reported the matter to the public security authorities and will pursue legal action against the spreaders of rumors [1][2]. Summary by Sections - The company discovered serious false information about itself on online platforms, which was confirmed to be fabricated and published on an overseas website. The nature of the content includes political rumors, which the company deems extremely malicious [2]. - The individual responsible for the false information, identified as Li, previously served as the marketing director at Huaxi Xinyu Investment Co., Ltd. Li had a history of embezzlement, having fraudulently obtained 9 million yuan that was supposed to be paid to a brokerage firm. This incident was uncovered during an annual report review [2]. - Following the discovery of Li's actions, the company reported the case to the public security authorities, which led to a criminal prosecution based on the embezzlement charge. During the investigation, Li attempted to mitigate his punishment by writing an apology letter, but the company refused to entertain any additional compensation demands beyond the return of the embezzled funds [2]. - As of July 25, Huaxi Biological's stock closed at 53.83 yuan per share, with a market capitalization of 25.9 billion yuan [2].

华熙生物官方微博发布《关于网络不实信息的严正声明》称，昨日晚间发现部分网络平台用户发布关于 公司的严重不实信息。经核实，信息发布于境外网站，内容纯属捏造，恶意歪曲事实，其中部分内容涉 及政治谣言，性质极其恶劣。经查，该信息发布者李某曾任华熙昕宇投资有限公司市场部总监，事发前 曾在华熙工作18个月。 ...